Indivior PLC (INDV)
32.97
-0.57 (-1.70%)
Inactive · Last trade price on Jan 23, 2026
Indivior Revenue
Indivior had revenue of $314.00M in the quarter ending September 30, 2025, with 2.28% growth. This brings the company's revenue in the last twelve months to $1.18B, down -0.25% year-over-year. In the year 2024, Indivior had annual revenue of $1.19B with 8.69% growth.
Revenue (ttm)
$1.18B
Revenue Growth
-0.25%
P/S Ratio
3.50
Revenue / Employee
$1,180,000
Employees
1,000
Market Cap
4.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.19B | 95.00M | 8.69% |
| Dec 31, 2023 | 1.09B | 192.00M | 21.31% |
| Dec 31, 2022 | 901.00M | 110.00M | 13.91% |
| Dec 31, 2021 | 791.00M | 144.00M | 22.26% |
| Dec 31, 2020 | 647.00M | -138.00M | -17.58% |
| Dec 31, 2019 | 785.00M | -220.00M | -21.89% |
| Dec 31, 2018 | 1.01B | -88.00M | -8.05% |
| Dec 31, 2017 | 1.09B | 35.00M | 3.31% |
| Dec 31, 2016 | 1.06B | 44.00M | 4.34% |
| Dec 31, 2015 | 1.01B | -101.00M | -9.06% |
| Dec 31, 2014 | 1.12B | -101.00M | -8.31% |
| Dec 31, 2013 | 1.22B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionINDV News
- 4 days ago - Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder - GlobeNewsWire
- 12 days ago - Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse - GlobeNewsWire
- 20 days ago - Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th - GlobeNewsWire
- 4 weeks ago - New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities - GlobeNewsWire
- 6 weeks ago - National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder - GlobeNewsWire
- 6 weeks ago - Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering - GlobeNewsWire
- 6 weeks ago - Indivior Announces Proposed Convertible Senior Notes Offering - GlobeNewsWire
- 7 weeks ago - New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder - GlobeNewsWire